Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Occurrence of new or more severe headaches following COVID-19 is associated with markers of microglial activation and peripheral sensitization: results from a prospective cohort study

Fig. 2

Comparison of VEGF (A), TGF-ß1 (B), CX3CL1 (C) and ß-NGF (D) concentrations for the 4 post-COVID headache groups: no headaches, unchanged headaches, more severe headaches, and newly onset headaches. Patient samples were analyzed for biomarker concentrations of VEGF (A), TGF-ß1 (B), CX3CL1 (C), and ß-NGF (D) across the four post-COVID headache groups: those with no headaches, unchanged headaches, more severe headaches, and newly onset headaches. Only biomarkers showing significant values < 0.05 in the global analysis of all biomarkers using the Chi-Square test are presented. Box and Whiskers plots are depicted

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us